Search

Your search keyword '"Hasseli, Rebecca"' showing total 212 results
Start Over Author "Hasseli, Rebecca"
212 results on '"Hasseli, Rebecca"'

2. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis: data from the COVID-19 PsoProtect and Global Rheumatology Alliance physician-reported registries

Author

Machado, Pedro M, Schäfer, Martin, Mahil, Satveer K, Liew, Jean, Gossec, Laure, Dand, Nick, Pfeil, Alexander, Strangfeld, Anja, Regierer, Anne Constanze, Fautrel, Bruno, Alonso, Carla Gimena, Saad, Carla GS, Griffiths, Christopher EM, Lomater, Claudia, Miceli-Richard, Corinne, Wendling, Daniel, Rodriguez, Deshire Alpizar, Wiek, Dieter, Mateus, Elsa F, Sirotich, Emily, Soriano, Enrique R, Ribeiro, Francinne Machado, Omura, Felipe, Martins, Frederico Rajão, Santos, Helena, Dau, Jonathan, Barker, Jonathan N, Hausmann, Jonathan, Hyrich, Kimme L, Gensler, Lianne, Silva, Ligia, Jacobsohn, Lindsay, Carmona, Loreto, Pinheiro, Marcelo M, Zelaya, Marcos David, de los Ángeles Severina, María, Yates, Mark, Dubreuil, Maureen, Gore-Massy, Monique, Romeo, Nicoletta, Haroon, Nigil, Sufka, Paul, Grainger, Rebecca, Hasseli, Rebecca, Lawson-Tovey, Saskia, Bhana, Suleman, Pham, Thao, Olofsson, Tor, Bautista-Molano, Wilson, Wallace, Zachary S, Yiu, Zenas ZN, Yazdany, Jinoos, Robinson, Philip C, and Smith, Catherine H

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Aging, Clinical Research, Arthritis, Autoimmune Disease, Psoriasis, Good Health and Well Being, Adult, Humans, Male, Arthritis, Psoriatic, Rheumatology, COVID-19, Axial Spondyloarthritis, Physicians, Glucocorticoids, Interleukin-12, Registries, Covid-19, Psoriatic, Autoimmunity, Spondylitis, Ankylosing, Spondylitis, Ankylosing, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesTo investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).MethodsDemographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression.ResultsOf 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25-2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39-2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42-0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19.ConclusionOlder age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics.

Published
2023

3. Characteristics and Outcomes of People With Gout Hospitalized Due to COVID‐19: Data From the COVID‐19 Global Rheumatology Alliance Physician‐Reported Registry

Author

Jatuworapruk, Kanon, Montgomery, Anna, Gianfrancesco, Milena, Conway, Richard, Durcan, Laura, Graef, Elizabeth R, Jayatilleke, Aruni, Keen, Helen, Kilian, Adam, Young, Kristen, Carmona, Loreto, Cogo, Adriana Karina, Duarte‐García, Alí, Gossec, Laure, Hasseli, Rebecca, Hyrich, Kimme L, Langlois, Vincent, Lawson‐Tovey, Saskia, Malcata, Armando, Mateus, Elsa F, Schafer, Martin, Scirè, Carlo Alberto, Sigurdardottir, Valgerdur, Sparks, Jeffrey A, Strangfeld, Anja, Xavier, Ricardo M, Bhana, Suleman, Gore‐Massy, Monique, Hausmann, Jonathan, Liew, Jean W, Sirotich, Emily, Sufka, Paul, Wallace, Zach, Machado, Pedro M, Yazdany, Jinoos, Grainger, Rebecca, and Robinson, Philip C

Subjects
Prevention, Clinical Research, Good Health and Well Being
Abstract

ObjectiveTo describe people with gout who were diagnosed with coronavirus disease 2019 (COVID-19) and hospitalized and to characterize their outcomes.MethodsData on patients with gout hospitalized for COVID-19 between March 12, 2020, and October 25, 2021, were extracted from the COVID-19 Global Rheumatology Alliance registry. Descriptive statistics were used to describe the demographics, comorbidities, medication exposures, and COVID-19 outcomes including oxygenation or ventilation support and death.ResultsOne hundred sixty-three patients with gout who developed COVID-19 and were hospitalized were included. The mean age was 63 years, and 85% were male. The majority of the group lived in the Western Pacific Region (35%) and North America (18%). Nearly half (46%) had two or more comorbidities, with hypertension (56%), cardiovascular disease (28%), diabetes mellitus (26%), chronic kidney disease (25%), and obesity (23%) being the most common. Glucocorticoids and colchicine were used pre-COVID-19 in 11% and 12% of the cohort, respectively. Over two thirds (68%) of the cohort required supplemental oxygen or ventilatory support during hospitalization. COVID-19-related death was reported in 16% of the overall cohort, with 73% of deaths documented in people with two or more comorbidities.ConclusionThis cohort of people with gout and COVID-19 who were hospitalized had high frequencies of ventilatory support and death. This suggests that patients with gout who were hospitalized for COVID-19 may be at risk of poor outcomes, perhaps related to known risk factors for poor outcomes, such as age and presence of comorbidity.

Published
2022

4. Development of a Prediction Model for COVID‐19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry

Author

Izadi, Zara, Gianfrancesco, Milena A, Aguirre, Alfredo, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson‐Tovey, Saskia, Kearsley‐Fleet, Lianne, Schaefer, Martin, Seet, Andrea M, Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Al‐Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y‐T, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Duarte‐García, Alí, Valenzuela‐Almada, Maria O, Ugarte‐Gil, Manuel F, Ribeiro, Sandra Lúcia Euzébio, de Oliveira Marinho, Adriana, de Azevedo Valadares, Lilian David, Di Giuseppe, Daniela, Hasseli, Rebecca, Richter, Jutta G, Pfeil, Alexander, Schmeiser, Tim, Isnardi, Carolina A, Torres, Alvaro A Reyes, Alle, Gelsomina, Saurit, Verónica, Zanetti, Anna, Carrara, Greta, Labreuche, Julien, Barnetche, Thomas, Herasse, Muriel, Plassart, Samira, Santos, Maria José, Rodrigues, Ana Maria, Robinson, Philip C, Machado, Pedro M, Sirotich, Emily, Liew, Jean W, Hausmann, Jonathan S, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Costello, Wendy, Wallace, Zachary S, Yazdany, Jinoos, and Registry, Global Rheumatology Alliance

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Lung, Prevention, Rare Diseases, Arthritis, Autoimmune Disease, Good Health and Well Being, Global Rheumatology Alliance Registry, Clinical sciences
Abstract

ObjectiveSome patients with rheumatic diseases might be at higher risk for coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). We aimed to develop a prediction model for COVID-19 ARDS in this population and to create a simple risk score calculator for use in clinical settings.MethodsData were derived from the COVID-19 Global Rheumatology Alliance Registry from March 24, 2020, to May 12, 2021. Seven machine learning classifiers were trained on ARDS outcomes using 83 variables obtained at COVID-19 diagnosis. Predictive performance was assessed in a US test set and was validated in patients from four countries with independent registries using area under the curve (AUC), accuracy, sensitivity, and specificity. A simple risk score calculator was developed using a regression model incorporating the most influential predictors from the best performing classifier.ResultsThe study included 8633 patients from 74 countries, of whom 523 (6%) had ARDS. Gradient boosting had the highest mean AUC (0.78; 95% confidence interval [CI]: 0.67-0.88) and was considered the top performing classifier. Ten predictors were identified as key risk factors and were included in a regression model. The regression model that predicted ARDS with 71% (95% CI: 61%-83%) sensitivity in the test set, and with sensitivities ranging from 61% to 80% in countries with independent registries, was used to develop the risk score calculator.ConclusionWe were able to predict ARDS with good sensitivity using information readily available at COVID-19 diagnosis. The proposed risk score calculator has the potential to guide risk stratification for treatments, such as monoclonal antibodies, that have potential to reduce COVID-19 disease progression.

Published
2022

5. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Yeoh, Su-Ann, Gianfrancesco, Milena, Lawson-Tovey, Saskia, Hyrich, Kimme L, Strangfeld, Anja, Gossec, Laure, Carmona, Loreto, Mateus, Elsa F, Schäfer, Martin, Richez, Christophe, Hachulla, Eric, Holmqvist, Marie, Scirè, Carlo Alberto, Lorenz, Hanns-Martin, Voll, Reinhard E, Hasseli, Rebecca, Jayatilleke, Arundathi, Hsu, Tiffany Y-T, D’Silva, Kristin M, Pimentel-Quiroz, Victor R, del Mercado, Monica Vasquez, Shinjo, Samuel Katsuyuki, dos Reis Neto, Edgard Torres, da Rocha, Laurindo Ferreira, de Oliveira e Silva Montandon, Ana Carolina, Pons-Estel, Guillermo J, Ornella, Sofía, Exeni, Maria Eugenia D'Angelo, Velozo, Edson, Jordan, Paula, Sirotich, Emily, Hausmann, Jonathan S, Liew, Jean W, Jacobsohn, Lindsay, Gore-Massy, Monique, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Wallace, Zachary, Robinson, Philip C, Yazdany, Jinoos, and Machado, Pedro M

Subjects
Aging, Autoimmune Disease, Rare Diseases, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Adult, COVID-19, COVID-19 Testing, Female, Humans, Male, Myositis, Physicians, Prednisolone, Registries, Rheumatology, Rituximab, polymyositis, dermatomyositis, outcome assessment, health care, epidemiology, COVID-19 Global Rheumatology Alliance, outcome assessment, health care, Clinical Sciences
Abstract

ObjectivesTo investigate factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy (IIM).MethodsDemographic data, clinical characteristics and COVID-19 outcome severity of adults with IIM were obtained from the COVID-19 Global Rheumatology Alliance physician-reported registry. A 3-point ordinal COVID-19 severity scale was defined: (1) no hospitalisation, (2) hospitalisation (and no death) and (3) death. ORs were estimated using multivariable ordinal logistic regression. Sensitivity analyses were performed using a 4-point ordinal scale: (1) no hospitalisation, (2) hospitalisation with no oxygen (and no death), (3) hospitalisation with oxygen/ventilation (and no death) and 4) death.ResultsOf 348 patients, 48% were not hospitalised, 39% were hospitalised (and did not die) and 13% died. Older age (OR=1.59/decade, 95% CI 1.31 to 1.91), high disease activity (OR=3.50, 95% CI 1.25 to 9.83; vs remission), ≥2 comorbidities (OR=2.63, 95% CI 1.39 to 4.98; vs none), prednisolone-equivalent dose >7.5 mg/day (OR=2.40, 95% CI 1.09 to 5.28; vs no intake) and exposure to rituximab (OR=2.71, 95% CI 1.28 to 5.72; vs conventional synthetic disease-modifying antirheumatic drugs only) were independently associated with severe COVID-19. In addition to these variables, in the sensitivity analyses, male sex (OR range: 1.65-1.83; vs female) was also significantly associated with severe outcomes, while COVID-19 diagnosis after 1 October 2020 (OR range: 0.51-0.59; vs on/before 15 June 2020) was significantly associated with less severe outcomes, but these associations were not significant in the main model (OR=1.57, 95% CI 0.95 to 2.59; and OR=0.61, 95% CI 0.37 to 1.00; respectively).ConclusionsThis is the first large registry data on outcomes of COVID-19 in people with IIM. Older age, male sex, higher comorbidity burden, high disease activity, prednisolone-equivalent dose >7.5 mg/day and rituximab exposure were associated with severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with IIM.

Published
2022

6. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

Author

Izadi, Zara, Gianfrancesco, Milena A, Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Ja, Clairissa, Taylor, Tiffany, Shidara, Kie, Danila, Maria I, Wysham, Katherine D, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Al-Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Duarte-García, Alí, Valenzuela-Almada, Maria O, Ugarte-Gil, Manuel F, Ljung, Lotta, Scirè, Carlo A, Carrara, Greta, Hachulla, Eric, Richez, Christophe, Cacoub, Patrice, Thomas, Thierry, Santos, Maria J, Bernardes, Miguel, Hasseli, Rebecca, Regierer, Anne, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Pons-Estel, Guillermo, Tanten, Romina, Nieto, Romina E, Pisoni, Cecilia N, Tissera, Yohana S, Xavier, Ricardo, Marques, Claudia D Lopes, Pileggi, Gecilmara CS, Robinson, Philip C, Machado, Pedro M, Sirotich, Emily, Liew, Jean W, Hausmann, Jonathan S, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Gore-Massy, Monique, Wallace, Zachary S, Yazdany, Jinoos, Registry, COVID-19 Global Rheumatology Alliance, Dahou, Brahim, Gómez, Gimena, Roberts, Karen, Baez, Roberto M, Coello, Vanessa V Castro, Salinas, María J Haye, Maldonado, Federico N, Reyes, Alvaro A, Alle, Gelsomina, Ficco, Hernán Maldonado, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan A, Schmid, Maria M, Cosatti, Micaela, Gamba, Maria J, Leandro, Carlevaris, Cusa, María A, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Elkin, Maria S Gálvez, Medina, María A, Savio, Veronica, Tessel, Romina Rojas, Alamino, Rodolfo P, Werner, Marina L, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, and Lucero, Luciana Gonzalez

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Women's Health, Social Determinants of Health, Infectious Diseases, Coronaviruses, Emerging Infectious Diseases, Good Health and Well Being, COVID-19 Global Rheumatology Alliance Registry, Clinical sciences
Abstract

BackgroundDifferences in the distribution of individual-level clinical risk factors across regions do not fully explain the observed global disparities in COVID-19 outcomes. We aimed to investigate the associations between environmental and societal factors and country-level variations in mortality attributed to COVID-19 among people with rheumatic disease globally.MethodsIn this observational study, we derived individual-level data on adults (aged 18-99 years) with rheumatic disease and a confirmed status of their highest COVID-19 severity level from the COVID-19 Global Rheumatology Alliance (GRA) registry, collected between March 12, 2020, and Aug 27, 2021. Environmental and societal factors were obtained from publicly available sources. The primary endpoint was mortality attributed to COVID-19. We used a multivariable logistic regression to evaluate independent associations between environmental and societal factors and death, after controlling for individual-level risk factors. We used a series of nested mixed-effects models to establish whether environmental and societal factors sufficiently explained country-level variations in death.Findings14 044 patients from 23 countries were included in the analyses. 10 178 (72·5%) individuals were female and 3866 (27·5%) were male, with a mean age of 54·4 years (SD 15·6). Air pollution (odds ratio 1·10 per 10 μg/m3 [95% CI 1·01-1·17]; p=0·0105), proportion of the population aged 65 years or older (1·19 per 1% increase [1·10-1·30]; p

Published
2022

7. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

Author

Ugarte-Gil, Manuel Francisco, Alarcón, Graciela S, Izadi, Zara, Duarte-García, Ali, Reátegui-Sokolova, Cristina, Clarke, Ann Elaine, Wise, Leanna, Pons-Estel, Guillermo J, Santos, Maria Jose, Bernatsky, Sasha, Ribeiro, Sandra Lúcia Euzébio, Al Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, Patel, Naomi J, Gilbert, Emily L, Valenzuela-Almada, Maria O, Jönsen, Andreas, Landolfi, Gianpiero, Fredi, Micaela, Goulenok, Tiphaine, Devaux, Mathilde, Mariette, Xavier, Queyrel, Viviane, Romão, Vasco C, Sequeira, Graca, Hasseli, Rebecca, Hoyer, Bimba, Voll, Reinhard E, Specker, Christof, Baez, Roberto, Castro-Coello, Vanessa, Ficco, Hernan Maldonado, Neto, Edgard Torres Reis, Ferreira, Gilda Aparecida Aparecida, Monticielo, Odirlei Andre André, Sirotich, Emily, Liew, Jean, Hausmann, Jonathan, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Costello, Wendy, Wallace, Zachary S, Jacobsohn, Lindsay, Taylor, Tiffany, Ja, Clairissa, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schäfer, Martin, Machado, Pedro M, Robinson, Philip C, Gianfrancesco, Milena, and Yazdany, Jinoos

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Clinical Research, Infectious Diseases, Lupus, Emerging Infectious Diseases, Minority Health, Coronaviruses, Autoimmune Disease, Women's Health, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Inflammatory and immune system, Good Health and Well Being, COVID-19, Humans, Lupus Erythematosus, Systemic, Male, Prednisone, Rheumatology, Severity of Illness Index, lupus erythematosus, systemic, epidemiology, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

AimTo determine characteristics associated with more severe outcomes in a global registry of people with systemic lupus erythematosus (SLE) and COVID-19.MethodsPeople with SLE and COVID-19 reported in the COVID-19 Global Rheumatology Alliance registry from March 2020 to June 2021 were included. The ordinal outcome was defined as: (1) not hospitalised, (2) hospitalised with no oxygenation, (3) hospitalised with any ventilation or oxygenation and (4) death. A multivariable ordinal logistic regression model was constructed to assess the relationship between COVID-19 severity and demographic characteristics, comorbidities, medications and disease activity.ResultsA total of 1606 people with SLE were included. In the multivariable model, older age (OR 1.03, 95% CI 1.02 to 1.04), male sex (1.50, 1.01 to 2.23), prednisone dose (1-5 mg/day 1.86, 1.20 to 2.66, 6-9 mg/day 2.47, 1.24 to 4.86 and ≥10 mg/day 1.95, 1.27 to 2.99), no current treatment (1.80, 1.17 to 2.75), comorbidities (eg, kidney disease 3.51, 2.42 to 5.09, cardiovascular disease/hypertension 1.69, 1.25 to 2.29) and moderate or high SLE disease activity (vs remission; 1.61, 1.02 to 2.54 and 3.94, 2.11 to 7.34, respectively) were associated with more severe outcomes. In age-adjusted and sex-adjusted models, mycophenolate, rituximab and cyclophosphamide were associated with worse outcomes compared with hydroxychloroquine; outcomes were more favourable with methotrexate and belimumab.ConclusionsMore severe COVID-19 outcomes in individuals with SLE are largely driven by demographic factors, comorbidities and untreated or active SLE. Patients using glucocorticoids also experienced more severe outcomes.

Published
2022

8. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

Author

Sattui, Sebastian E, Conway, Richard, Putman, Michael S, Seet, Andrea M, Gianfrancesco, Milena A, Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L, Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Maldonado, Federico Nicolas, Mariz, Henrique Ataide, de Sousa Studart, Samia Araujo, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stéphane, Maria, Alexandre TJ, Chazerain, Pascal, Hasseli, Rebecca, Müller-Ladner, Ulf, Hoyer, Bimba F, Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Al-Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-García, Alí, Ugarte-Gil, Manuel, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S, Sufka, Paul, Bhana, Suleman, Liew, Jean W, Grainger, Rebecca, Machado, Pedro M, Wallace, Zachary S, Yazdany, Jinoos, Robinson, Philip C, Alliance, Global Rheumatology, Dahou, Brahim, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Ribeiro, Francinne Machado, Ribeiro, Sandra Lucia Euzebio, Pinheiro, Marcelo, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Coello, Vanessa Castro, Salinas, María J Haye, Torres, Alvaro Andres Reyes, Alle, Gelsomina, Tanten, Romina, Ficco, Hernán Maldonado, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Elkin, Maria Soledad Gálvez, Medina, María Alejandra, and Savio, Veronica

Subjects
Aging, Arthritis, Autoimmune Disease, Clinical Research, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Inflammatory and immune system, Global Rheumatology Alliance
Abstract

BackgroundPatients with primary systemic vasculitis or polymyalgia rheumatica might be at a high risk for poor COVID-19 outcomes due to the treatments used, the potential organ damage cause by primary systemic vasculitis, and the demographic factors associated with these conditions. We therefore aimed to investigate factors associated with COVID-19 outcomes in patients with primary systemic vasculitis or polymyalgia rheumatica.MethodsIn this retrospective cohort study, adult patients (aged ≥18 years) diagnosed with COVID-19 between March 12, 2020, and April 12, 2021, who had a history of primary systemic vasculitis (antineutrophil cytoplasmic antibody [ANCA]-associated vasculitis, giant cell arteritis, Behçet's syndrome, or other vasculitis) or polymyalgia rheumatica, and were reported to the COVID-19 Global Rheumatology Alliance registry were included. To assess COVID-19 outcomes in patients, we used an ordinal COVID-19 severity scale, defined as: (1) no hospitalisation; (2) hospitalisation without supplemental oxygen; (3) hospitalisation with any supplemental oxygen or ventilation; or (4) death. Multivariable ordinal logistic regression analyses were used to estimate odds ratios (ORs), adjusting for age, sex, time period, number of comorbidities, smoking status, obesity, glucocorticoid use, disease activity, region, and medication category. Analyses were also stratified by type of rheumatic disease.FindingsOf 1202 eligible patients identified in the registry, 733 (61·0%) were women and 469 (39·0%) were men, and their mean age was 63·8 years (SD 17·1). A total of 374 (31·1%) patients had polymyalgia rheumatica, 353 (29·4%) had ANCA-associated vasculitis, 183 (15·2%) had giant cell arteritis, 112 (9·3%) had Behçet's syndrome, and 180 (15·0%) had other vasculitis. Of 1020 (84·9%) patients with outcome data, 512 (50·2%) were not hospitalised, 114 (11·2%) were hospitalised and did not receive supplemental oxygen, 239 (23·4%) were hospitalised and received ventilation or supplemental oxygen, and 155 (15·2%) died. A higher odds of poor COVID-19 outcomes were observed in patients who were older (per each additional decade of life OR 1·44 [95% CI 1·31-1·57]), were male compared with female (1·38 [1·05-1·80]), had more comorbidities (per each additional comorbidity 1·39 [1·23-1·58]), were taking 10 mg/day or more of prednisolone compared with none (2·14 [1·50-3·04]), or had moderate, or high or severe disease activity compared with those who had disease remission or low disease activity (2·12 [1·49-3·02]). Risk factors varied among different disease subtypes.InterpretationAmong patients with primary systemic vasculitis and polymyalgia rheumatica, severe COVID-19 outcomes were associated with variable and largely unmodifiable risk factors, such as age, sex, and number of comorbidities, as well as treatments, including high-dose glucocorticoids. Our results could be used to inform mitigation strategies for patients with these diseases.FundingAmerican College of Rheumatology and the European Alliance of Associations for Rheumatology.

Published
2021

9. Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry

Author

Sparks, Jeffrey A, Wallace, Zachary S, Seet, Andrea M, Gianfrancesco, Milena A, Izadi, Zara, Hyrich, Kimme L, Strangfeld, Anja, Gossec, Laure, Carmona, Loreto, Mateus, Elsa F, Lawson-Tovey, Saskia, Trupin, Laura, Rush, Stephanie, Katz, Patricia, Schmajuk, Gabriela, Jacobsohn, Lindsay, Wise, Leanna, Gilbert, Emily L, Duarte-García, Ali, Valenzuela-Almada, Maria O, Pons-Estel, Guillermo J, Isnardi, Carolina A, Berbotto, Guillermo A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Kearsley-Fleet, Lianne, Schäfer, Martin, Ribeiro, Sandra Lúcia Euzébio, Al Emadi, Samar, Tidblad, Liselotte, Scirè, Carlo Alberto, Raffeiner, Bernd, Thomas, Thierry, Flipo, René-Marc, Avouac, Jérôme, Seror, Raphaèle, Bernardes, Miguel, Cunha, Maria Margarida, Hasseli, Rebecca, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Specker, Christof, de Souza, Viviane Angelina, da Mota, Licia Maria Henrique, Gomides, Ana Paula Monteiro, Dieudé, Philippe, Nikiphorou, Elena, Kronzer, Vanessa L, Singh, Namrata, Ugarte-Gil, Manuel F, Wallace, Beth, Akpabio, Akpabio, Thomas, Ranjeny, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Hausmann, Jonathan S, Liew, Jean W, Sirotich, Emily, Sufka, Paul, Robinson, Philip C, Machado, Pedro M, Yazdany, Jinoos, Dahou, Brahim, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Coello, Vanessa Castro, Salinas, María Haye, Maldonado, Federico Nicolas, Reyes, Alvaro Andres, Alle, Gelsomina, Tanten, Romina, Ficco, Hernán Maldonado, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Elkin, Maria Soledad, Medina, María Alejandra, Savio, Veronica, Tessel, Ivana Romina, Alamino, Rodolfo Perez, Werner, Marina Laura, Ornella, Sofía, and Casalla, Luciana

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Rheumatoid Arthritis, Emerging Infectious Diseases, Coronaviruses, Arthritis, Autoimmune Disease, 6.1 Pharmaceuticals, Inflammatory and immune system, Good Health and Well Being, Aged, Antirheumatic Agents, Arthritis, Rheumatoid, COVID-19, Female, Humans, Male, Middle Aged, Registries, SARS-CoV-2, Severity of Illness Index, COVID-19 Global Rheumatology Alliance, Covid-19, abatacept, rheumatoid arthritis, rituximab, tumour necrosis factor inhibitors, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveTo investigate baseline use of biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis (RA).MethodsWe analysed the COVID-19 Global Rheumatology Alliance physician registry (from 24 March 2020 to 12 April 2021). We investigated b/tsDMARD use for RA at the clinical onset of COVID-19 (baseline): abatacept (ABA), rituximab (RTX), Janus kinase inhibitors (JAKi), interleukin 6 inhibitors (IL-6i) or tumour necrosis factor inhibitors (TNFi, reference group). The ordinal COVID-19 severity outcome was (1) no hospitalisation, (2) hospitalisation without oxygen, (3) hospitalisation with oxygen/ventilation or (4) death. We used ordinal logistic regression to estimate the OR (odds of being one level higher on the ordinal outcome) for each drug class compared with TNFi, adjusting for potential baseline confounders.ResultsOf 2869 people with RA (mean age 56.7 years, 80.8% female) on b/tsDMARD at the onset of COVID-19, there were 237 on ABA, 364 on RTX, 317 on IL-6i, 563 on JAKi and 1388 on TNFi. Overall, 613 (21%) were hospitalised and 157 (5.5%) died. RTX (OR 4.15, 95% CI 3.16 to 5.44) and JAKi (OR 2.06, 95% CI 1.60 to 2.65) were each associated with worse COVID-19 severity compared with TNFi. There were no associations between ABA or IL6i and COVID-19 severity.ConclusionsPeople with RA treated with RTX or JAKi had worse COVID-19 severity than those on TNFi. The strong association of RTX and JAKi use with poor COVID-19 outcomes highlights prioritisation of risk mitigation strategies for these people.

Published
2021

11. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry

Author

Strangfeld, Anja, Schäfer, Martin, Gianfrancesco, Milena A, Lawson-Tovey, Saskia, Liew, Jean W, Ljung, Lotta, Mateus, Elsa F, Richez, Christophe, Santos, Maria J, Schmajuk, Gabriela, Scirè, Carlo A, Sirotich, Emily, Sparks, Jeffrey A, Sufka, Paul, Thomas, Thierry, Trupin, Laura, Wallace, Zachary S, Al-Adely, Sarah, Bachiller-Corral, Javier, Bhana, Suleman, Cacoub, Patrice, Carmona, Loreto, Costello, Ruth, Costello, Wendy, Gossec, Laure, Grainger, Rebecca, Hachulla, Eric, Hasseli, Rebecca, Hausmann, Jonathan S, Hyrich, Kimme L, Izadi, Zara, Jacobsohn, Lindsay, Katz, Patricia, Kearsley-Fleet, Lianne, Robinson, Philip C, Yazdany, Jinoos, Machado, Pedro M, Dahou, Brahim, Pinheiro, Marcelo, Ribeiro, Francinne M, Chassin-Trubert, Anne-Marie, Ibáñez, Sebastián, Dong, Lingli, Cajas, Lui, Hamoud, Hesham, Avouac, Jérôme, Belin, Véronique, Borie, Raphaël, Chazerain, Pascal, Chevalier, Xavier, Claudepierre, Pascal, Clavel, Gaëlle, Colette-Cedoz, Marie-Eve, Combe, Bernard, Constant, Elodie, Costedoat-Chalumeau, Nathalie, Desmurs, Marie, Devauchelle-Pensec, Valérie, Devaux, Mathilde, Dhote, Robin, Dieudonné, Yannick, Domont, Fanny, Duret, Pierre-Marie, Ebbo, Mikaël, Ebstein, Esther, Mahou, Soumaya El, Fautrel, Bruno, Felten, Renaud, Flipo, René-Marc, Foltz, Violaine, Froissart, Antoine, Galland, Joris, Gaud-Listrat, Véronique, Georgin-Lavialle, Sophie, Giraud-Morelet, Aude, Quitrec, Jeanine S Giraudet-Le, Goupille, Philippe, Govindaraju-Audouard, Sophie, Grados, Franck, Guillaume-Czitrom, Séverine, Hermet, Marion, Hittinger-Roux, Ambre, Hudry, Christophe, Kone-Paut, Isabelle, La Batide Alanore, Sylvain, Lafforgue, Pierre, Lahalle, Sophie, Lambrecht, Isabelle, Langlois, Vincent, Larbre, Jean-Paul, Ledoult, Emmanuel, Leroux, Christophe, Liote, Frédéric, Maria, Alexandre TJ, Marotte, Hubert, Mekinian, Arsène, Melki, Isabelle, Messer, Laurent, Michel, Catherine, and Morel, Gauthier

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Infectious Diseases, Autoimmune Disease, Arthritis, Coronaviruses, Emerging Infectious Diseases, Cardiovascular, Inflammatory and immune system, Good Health and Well Being, Aged, Antirheumatic Agents, COVID-19, Comorbidity, Female, Global Health, Glucocorticoids, Humans, Male, Middle Aged, Odds Ratio, Registries, Rheumatic Diseases, Rheumatology, SARS-CoV-2, antirheumatic agents, autoimmune diseases, epidemiology, glucocorticoids, outcome assessment, health care, COVID-19 Global Rheumatology Alliance, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectivesTo determine factors associated with COVID-19-related death in people with rheumatic diseases.MethodsPhysician-reported registry of adults with rheumatic disease and confirmed or presumptive COVID-19 (from 24 March to 1 July 2020). The primary outcome was COVID-19-related death. Age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity and medications were included as covariates in multivariable logistic regression models. Analyses were further stratified according to rheumatic disease category.ResultsOf 3729 patients (mean age 57 years, 68% female), 390 (10.5%) died. Independent factors associated with COVID-19-related death were age (66-75 years: OR 3.00, 95% CI 2.13 to 4.22; >75 years: 6.18, 4.47 to 8.53; both vs ≤65 years), male sex (1.46, 1.11 to 1.91), hypertension combined with cardiovascular disease (1.89, 1.31 to 2.73), chronic lung disease (1.68, 1.26 to 2.25) and prednisolone-equivalent dosage >10 mg/day (1.69, 1.18 to 2.41; vs no glucocorticoid intake). Moderate/high disease activity (vs remission/low disease activity) was associated with higher odds of death (1.87, 1.27 to 2.77). Rituximab (4.04, 2.32 to 7.03), sulfasalazine (3.60, 1.66 to 7.78), immunosuppressants (azathioprine, cyclophosphamide, ciclosporin, mycophenolate or tacrolimus: 2.22, 1.43 to 3.46) and not receiving any disease-modifying anti-rheumatic drug (DMARD) (2.11, 1.48 to 3.01) were associated with higher odds of death, compared with methotrexate monotherapy. Other synthetic/biological DMARDs were not associated with COVID-19-related death.ConclusionAmong people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dosages. Caution may be required with rituximab, sulfasalazine and some immunosuppressants.

Published
2021

12. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID‐19 Global Rheumatology Alliance Registry

Author

Yazdany, Jinoos, Ware, Anna, Wallace, Zachary S., Bhana, Suleman, Grainger, Rebecca, Hachulla, Eric, Richez, Christophe, Cacoub, Patrice, Hausmann, Jonathan S., Liew, Jean W., Sirotich, Emily, Jacobsohn, Lindsay, Strangfeld, Anja, Mateus, Elsa F., Hyrich, Kimme L., Gossec, Laure, Carmona, Loreto, Lawson‐Tovey, Saskia, Kearsley‐Fleet, Lianne, Schaefer, Martin, Ribeiro, Sandra Lucia Euzebio, Al‐Emadi, Samar, Hasseli, Rebecca, Müller‐Ladner, Ulf, Specker, Christof, Schulze‐Koops, Hendrik, Bernardes, Miguel, Fraga, Vanessa Machado, Rodrigues, Ana Maria, Sparks, Jeffrey A., Ljung, Lotta, Di Giuseppe, Daniela, Tidblad, Liselotte, Wise, Leanna, Duarte‐García, Alí, Ugarte‐Gil, Manuel F., Colunga‐Pedraza, Iris Jazmín, Martínez‐Martínez, Marco Ulises, Alpizar‐Rodriguez, Deshire, Xavier, Ricardo Machado, Isnardi, Carolina A., Pera, Mariana, Pons‐Estel, Guillermo, Izadi, Zara, Gianfrancesco, Milena A., Carrara, Greta, Scirè, Carlo Alberto, Zanetti, Anna, and Machado, Pedro M.

Published
2024
Full Text
View/download PDF

13. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis

Author

Preuße, Corinna, Paesler, Barbara, Nelke, Christopher, Cengiz, Derya, Müntefering, Thomas, Roos, Andreas, Amelin, Damien, Allenbach, Yves, Uruha, Akinori, Dittmayer, Carsten, Hentschel, Andreas, Pawlitzki, Marc, Hoffmann, Sarah, Timm, Sara, Louis, Sarah Leonard, Dengler, Nora F., Wiendl, Heinz, Lünemann, Jan D., Sickmann, Albert, Hervier, Baptiste, Meuth, Sven G., Schneider, Udo, Schänzer, Anne, Krause, Sabine, Tomaras, Stylianos, Feist, Eugen, Hasseli, Rebecca, Goebel, Hans-Hilmar, Gallay, Laure, Streichenberger, Nathalie, Benveniste, Olivier, Stenzel, Werner, and Ruck, Tobias

Published
2022
Full Text
View/download PDF

14. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

Author

Dahou, Brahim, Gómez, Gimena, Roberts, Karen, Baez, Roberto M, Castro Coello, Vanessa V, Haye Salinas, María J, Maldonado, Federico N, Reyes, Alvaro A, Alle, Gelsomina, Tanten, Romina, Maldonado Ficco, Hernán, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan A, Schmid, Maria M, Cosatti, Micaela, Gamba, Maria J, Leandro, Carlevaris, Cusa, María A, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Gálvez Elkin, Maria S, Medina, María A, Savio, Veronica, Rojas Tessel, Romina, Alamino, Rodolfo P, Werner, Marina L, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, Gonzalez Lucero, Luciana, Romeo, Cecilia, Moyano, Sebastián, Barbich, Tatiana, Bertoli, Ana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla, Conti, Silvana, Lazaro, Maria A, Rodriguez Gil, Gustavo F, Risueño, Fabian, Quaglia, Maria I, Scafati, Julia, Cuchiaro, Natalia L, Rebak, Jonathan E, Pineda, Susana I, Calvo, María E, Picco, Eugenia, Yanzi, Josefina G, Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta S, Porta, Sabrina, Herscovich, Natalia, Velasco Zamora, José L, Kisluk, Boris, Castaños Menescardi, Maria S, Gallo, Rosana, Martire, María V, Maldini, Carla, Goizueta, Cecilia, de la Vega Fernandez, Sabrina S, Aeschlimann, Carolina, Subils, Gisela, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Machado Ribeiro, Francinne, Euzebio Ribeiro, Sandra L, Pinheiro, Marcelo, Ibáñez, Sebastián, Chassin Trubert, Anne-Marie, Dong, Lingli, Cajas, Lui, Barešić, Marko, Anić, Branimir, Ćulo, Melanie-Ivana, Pavelić, Tea A, Stranski, Kristina K, Karanovic, Boris, Vencovsky, Jiri, Píchová, Marta, Filkova, Maria, Hamoud, Hesham, Vassilopoulos, Dimitrios, Guzman Melgar, Gabriela M, So, Ho, Király, Márta, Vojdanian, Mahdi, Balbir Gurman, Alexandra, Abutiban, Fatemah, Zepa, Julija, Bulina, Inita, Bukauskiene, Loreta, Zazueta Montiel, Beatriz E, Castillo Ortiz, Angel A, Zamora Tehozol, Erick, Vega Morales, David, Cervántes Rosete, Diana, Martín Nares, Eduardo, Rodriguez Reyna, Tatiana S, Rull Gabayet, Marina, Alpízar Rodríguez, Deshiré, Irazoque, Fedra, Jimenez, Xochitl, Geurts van Bon, Lenny, Zijlstra, Theo, Hoekstra, Monique, Al Adhoubi, Nasra, Salim, Babur, Giraldo, Enrique, Salinas, Ariel, Ugarte Gil, Manuel, Nowakowski, Jarosław, Conway, Richard, Flood, Rachael, McCarthy, Geraldine, Felea, Ioana, Filipescu, Ileana, Rednic, Simona, Groseanu, Laura, Tamas, Maria M, Mlynarikova, Vanda, Skamlova, Martina, Zlnay, Martin, Mičeková, Dagmar, Capova, Lubica, Macejova, Zelmira, Šteňová, Emőke, Raffayova, Helena, Belakova, Gabriela, Strakova, Eva, Senčarová, Marieta, Žlnayová, Soňa, Sabová, Anna, Spisakova, Daniela, Oetterová, Mária, Lukacova, Olga, Bakosova, Martina, Hocevar, Alojzija, de la Torre Rubio, Natalia, Alegre Sancho, Juan J, Corteguera Coro, Montserrat, Cobeta Garcia, Juan C, Torres Martin, Maria C, Campos, Jose, Gomez Puerta, Jose A, Yardimci, Gozd K, Akar, Servet, Icacan, Ozan C, ÇELİK, Selda, Vasylets, Viktoriia, Yeoh, Su-Ann, Vandevelde, Claire, Dunt, Sasha, Leeder, Jane, Macphie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O'Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer, Warner, Elizabeth, Pilcher, James, Patel, Samir, Nikiphorou, Elena, Chadwick, Laura, Jones, Caroline M, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah, Jatwani, Shraddha, Baig, Sara, Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Morgan, Jennifer, Pfeifer, Emily, Skemp, Archibald, Wilson, Jeffrey, Wolff, Anne, Cepeda, Eduardo, Todd, Derrick, Hare, Denise, Calabrese, Cassandra, Adams, Christopher, Khosroshahi, Arezou, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline, Daver, Nicole, Harvey, Melissa, Kramer, Neil, Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Ruderman, Eric, Davis, William, Quinet, Robert, Scopelitis, Evangeline, Toribio, Karen, Webb Detiege, Tameka, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Jayatilleke, Arundathi, Zell, JoAnn, Bays, Alison, Dao, Kathryn, Ezzati, Fatemeh, Parks, Deborah, Karp, David, Quiceno, Guillermo, Izadi, Zara, Gianfrancesco, Milena A, Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Ja, Clairissa, Taylor, Tiffany, Shidara, Kie, Danila, Maria I, Wysham, Katherine D, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Al-Emadi, Samar, Sparks, Jeffrey A, Hsu, Tiffany Y-T, Patel, Naomi J, Wise, Leanna, Gilbert, Emily, Duarte-García, Alí, Valenzuela-Almada, Maria O, Ugarte-Gil, Manuel F, Ljung, Lotta, Scirè, Carlo A, Carrara, Greta, Hachulla, Eric, Richez, Christophe, Cacoub, Patrice, Thomas, Thierry, Santos, Maria J, Bernardes, Miguel, Hasseli, Rebecca, Regierer, Anne, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Pons-Estel, Guillermo, Nieto, Romina E, Pisoni, Cecilia N, Tissera, Yohana S, Xavier, Ricardo, Lopes Marques, Claudia D, Pileggi, Gecilmara C S, Robinson, Philip C, Machado, Pedro M, Sirotich, Emily, Liew, Jean W, Hausmann, Jonathan S, Sufka, Paul, Grainger, Rebecca, Bhana, Suleman, Gore-Massy, Monique, Wallace, Zachary S, and Yazdany, Jinoos

Published
2022
Full Text
View/download PDF

15. Small fiber involvement is independent from clinical pain in late-onset Pompe disease

Author

Enax-Krumova, Elena K., Dahlhaus, Iris, Görlach, Jonas, Claeys, Kristl G., Montagnese, Federica, Schneider, llka, Sturm, Dietrich, Fangerau, Tanja, Schlierbach, Hannah, Roth, Angela, Wanschitz, Julia V., Löscher, Wolfgang N., Güttsches, Anne-Katrin, Vielhaber, Stefan, Hasseli, Rebecca, Zunk, Lea, Krämer, Heidrun H., Hahn, Andreas, Schoser, Benedikt, Rosenbohm, Angela, and Schänzer, Anne

Published
2022
Full Text
View/download PDF

16. Updated recommendations of the German Society for Rheumatology for the care of patients with inflammatory rheumatic diseases in the context of the SARS-CoV-2/COVID-19 pandemic, including recommendations for COVID-19 vaccination

Author

Specker, Christof, Aries, Peer, Braun, Jürgen, Burmester, Gerd, Fischer-Betz, Rebecca, Hasseli, Rebecca, Holle, Julia, Hoyer, Bimba Franziska, Iking-Konert, Christof, Krause, Andreas, Krüger, Klaus, Krusche, Martin, Leipe, Jan, Lorenz, Hanns-Martin, Moosig, Frank, Schmale-Grede, Rotraud, Schneider, Matthias, Strangfeld, Anja, Voll, Reinhard, Voormann, Anna, Wagner, Ulf, and Schulze-Koops, Hendrik

Published
2021
Full Text
View/download PDF

17. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study

Author

Dahou, Brahim, Rath, Eva, Piette, Yves, Devinck, Mieke, Maeyaert, Bea, Machado Ribeiro, Francinne, Euzebio Ribeiro, Sandra Lucia, Pinheiro, Marcelo, Quintana, Rosana, Gómez, Gimena, Roberts, Karen, Baez, Roberto Miguel, Castro Coello, Vanessa, Haye Salinas, María J., Maldonado, Federico Nicolas, Reyes Torres, Alvaro Andres, Alle, Gelsomina, Tanten, Romina, Maldonado Ficco, Hernán, Nieto, Romina, Gobbi, Carla, Tissera, Yohana, Pisoni, Cecilia, Paula, Alba, Albiero, Juan Alejandro, Schmid, Maria Marcela, Cosatti, Micaela, Gamba, Maria Julieta, Leandro, Carlevaris, Cusa, María Alejandra, German, Noelia, Bellomio, Veronica, Takashima, Lorena, Pera, Mariana, Cogo, Karina, Gálvez Elkin, Maria Soledad, Medina, María Alejandra, Savio, Veronica, Rojas Tessel, Ivana Romina, Perez Alamino, Rodolfo, Werner, Marina Laura, Ornella, Sofía, Casalla, Luciana, de la Vega, Maria, Severina, María, García, Mercedes, Gonzalez Lucero, Luciana, Romeo, Cecilia, Moyano, Sebastián, Barbich, Tatiana, Bertoli, Ana, Baños, Andrea, Petruzzelli, Sandra, Matellan, Carla, Conti, Silvana, Lazaro, Ma. Alicia, Rodriguez Gil, Gustavo Fabián, Risueño, Fabian, Quaglia, Maria Isabel, Scafati, Julia, Cuchiaro, Natalia Lili, Rebak, Jonathan Eliseo, Pineda, Susana Isabel, Calvo, María Elena, Picco, Eugenia, Gallino Yanzi, Josefina, Maid, Pablo, Guaglianone, Debora, Morbiducci, Julieta Silvana, Porta, Sabrina, Herscovich, Natalia, Velasco Zamora, José Luis, Kisluk, Boris, Castaños Menescardi, Maria Sol, Gallo, Rosana, Martire, María Victoria, Maldini, Carla, Goizueta, Cecilia, de la Vega Fernandez, Sabrina Solange, Aeschlimann, Carolina, Subils, Gisela, Ibáñez, Sebastián, Chassin-Trubert, Anne-Marie, Dong, Lingli, Cajas, Lui, Barešic, Marko, Anic, Branimir, Culo, Melanie-Ivana, Pavelic, Tea Ahel, Kovacevic Stranski, Kristina, Karanovic, Boris, Vencovsky, Jiri, Píchová, Marta, Filkova, Maria, Hamoud, Hesham, Vassilopoulos, Dimitrios, Guzman Melgar, Gabriela Maria, So, Ho, Király, Márta, Vojdanian, Mahdi, Balbir-Gurman, Alexandra, Abutiban, Fatemah, Zepa, Julija, Bulina, Inita, Bukauskiene, Loreta, Zaueta, Beatriz, Castillo Ortiz, Angel Alejandro, Zamora Tehozol, Erick, Vega, David, Cervántes Rosete, Diana, Martín Nares, Eduardo, Rodriguez-Reyna, Tatiana Sofia, Rull Gabayet, Marina, Alpízar-Rodríguez, Deshiré, Irazoque, Fedra, Jimenez, Xochitl, Geurts-van Bon, Lenny, Zijlstra, Theo, Hoekstra, Monique, Al-Adhoubi, Nasra, Salim, Babur, Giraldo, Enrique, Salinas, Ariel, Ugarte-Gil, Manuel, Nowakowski, Jaroslaw, Al-Emadi, Samar, Conway, Richard, Flood, Rachael, McCarthy, Geraldine, Felea, Ioana, Filipescu, Ileana, Rednic, Simona, Groseanu, Laura, Tamas, Maria Magdelena, Mlynarikova, Vanda, Skamlova, Martina, Zlnay, Martin, Miceková, Dagmar, Capova, Lubica, Macejova, Zelmira, Štenová, Emoke, Raffayova, Helena, Belakova, Gabriela, Strakova, Eva, Sencarová, Marieta, Žlnayová, Sona, Anna Sabová, Anna, Spisakova, Daniela, Oetterová, Mária, Lukacova, Olga, Bakosova, Martina, Hocevar, Alojzija, de la Torre-Rubio, Natalia, Alegre Sancho, Juan José, Corteguera Coro, Montserrat, Cobeta Garcia, Juan Carlos, Torres Martin, Maria Carmen, Campos, Jose, Gomez Puerta, Jose A, Yardimci, Gozd Kubra, Akar, Servet, Icacan, Ozan Cemal, Çelik, Selda, Vasylets, Viktoriia, Yeoh, Su-Ann, Vandevelde, Claire, Dunt, Sasha, Leeder, Jane, Macphie, Elizabeth, Salerno, Rosaria, Graver, Christine, Williams, Katie, O'Reilly, Sheila, Devine, Kirsty, Tyler, Jennifer, Warner, Elizabeth, Pilcher, James, Patel, Samir, Nikiphorou, Elena, Chadwick, Laura, Jones, Caroline Mulvaney, Harrison, Beverley, Thornton, Lucy, O'Kane, Diana, Fusi, Lucia, Low, Audrey, Horton, Sarah, Jatwani, Shraddha, Baig, Sara, Bajwa, Hammad, Berglund, Vernon, Dahle, Angela, Dorman, Walter, Hargrove, Jody, Hilton, Maren, Lebedoff, Nicholas, Leonard, Susan, Morgan, Jennifer, Pfeifer, Emily, Skemp, Archibald, Wilson, Jeffrey, Wolff, Anne, Cepeda, Eduardo, D'Silva, Kristin, Hsu, Tiffany, Patel, Naomi, Sparks, Jeffrey, Todd, Derrick, Wallace, Zachary, Hare, Denise, Calabrese, Cassandra, Adams, Christopher, Khosroshahi, Arezou, Kilian, Adam, White, Douglas, Winter, Melanie, Fields, Theodore, Siegel, Caroline, Daver, Nicole, Harvey, Melissa, Kramer, Neil, Lamore, Concetta, Hogarty, Suneya, Yeter, Karen, Wise, Leanna, Siddique, Faizah, Ban, Byung, Tanner, Tamar, Ruderman, Eric, Davis, William, Quinet, Robert, Scopelitis, Evangeline, Toribio Toribio, Karen, Webb-Detiege, Tameka, Zakem, Jerald, Abbass, Khurram, Kepecs, Gilbert, Miranda, Lilliam, Guma, Michael, Haikal, Ammar, Mody, Sushama, Mueller, Daric, Jayatilleke, Arundathi, Zell, JoAnn, Bays, Alison, Dao, Kathryn, Fatemeh, Ezzati, Parks, Deborah, Karp, David, Quiceno, Guillermo, Sattui, Sebastian E, Putman, Michael S, Seet, Andrea M, Gianfrancesco, Milena A, Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L, Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Mariz, Henrique Ataide, de Sousa Studart, Samia Araujo, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stéphane, Maria, Alexandre TJ, Chazerain, Pascal, Hasseli, Rebecca, Müller-Ladner, Ulf, Hoyer, Bimba F, Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Sparks, Jeffrey A, Hsu, Tiffany Y-T, D’Silva, Kristin M, Patel, Naomi J, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-García, Alí, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F, Hyrich, Kimme L, Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S, Sufka, Paul, Bhana, Suleman, Liew, Jean W, Grainger, Rebecca, Machado, Pedro M, Wallace, Zachary S, Yazdany, Jinoos, and Robinson, Philip C

Published
2021
Full Text
View/download PDF

19. The protective effect of tumor necrosis factor-alpha inhibitors in COVID-19 in patients with inflammatory rheumatic diseases compared to the general population—A comparison of two German registries

Author

Hasseli, Rebecca, primary, Hanses, Frank, additional, Stecher, Melanie, additional, Specker, Christof, additional, Weise, Tobias, additional, Borgmann, Stefan, additional, Hasselberger, Martina, additional, Hertenstein, Bernd, additional, Hower, Martin, additional, Hoyer, Bimba F., additional, Koll, Carolin, additional, Krause, Andreas, additional, von Lilienfeld-Toal, Marie, additional, Lorenz, Hanns-Martin, additional, Merle, Uta, additional, Nunes de Miranda, Susana M., additional, Pletz, Mathias W., additional, Regierer, Anne C., additional, Richter, Jutta G., additional, Rieg, Siegbert, additional, Roemmele, Christoph, additional, Ruethrich, Maria M., additional, Schmeiser, Tim, additional, Schulze-Koops, Hendrik, additional, Strangfeld, Anja, additional, Vehreschild, Maria J.G.T., additional, Voit, Florian, additional, Voll, Reinhard E., additional, Vehreschild, Jörg Janne, additional, Müller-Ladner, Ulf, additional, and Pfeil, Alexander, additional

Published
2024
Full Text
View/download PDF

21. Aktualisierte Handlungsempfehlungen der Deutschen Gesellschaft für Rheumatologie für die Betreuung von Patienten mit entzündlich-rheumatischen Erkrankungen im Rahmen der SARS-CoV‑2/COVID‑19-Pandemie einschließlich Empfehlungen zur COVID‑19-Impfung

Author

Specker, Christof, Aries, Peer, Braun, Jürgen, Burmester, Gerd, Fischer-Betz, Rebecca, Hasseli, Rebecca, Holle, Julia, Hoyer, Bimba Franziska, Iking-Konert, Christof, Krause, Andreas, Krüger, Klaus, Krusche, Martin, Leipe, Jan, Lorenz, Hanns-Martin, Moosig, Frank, Schmale-Grede, Rotraud, Schneider, Matthias, Strangfeld, Anja, Voll, Reinhard, Voormann, Anna, Wagner, Ulf, and Schulze-Koops, Hendrik

Published
2021
Full Text
View/download PDF

25. Impact of Risk Factors on COVID‐19 Outcomes in Unvaccinated People with Rheumatic Diseases

Author

Yazdany, Jinoos, primary, Ware, Anna, additional, Wallace, Zachary S, additional, Bhana, Suleman, additional, Grainger, Rebecca, additional, Hachulla, Eric, additional, Richez, Christophe, additional, Cacoub, Patrice, additional, Hausmann, Jonathan S, additional, Liew, Jean W, additional, Sirotich, Emily, additional, Jacobsohn, Lindsay, additional, Strangfeld, Anja, additional, Mateus, Elsa F, additional, Hyrich, Kimme L, additional, Gossec, Laure, additional, Carmona, Loreto, additional, Lawson‐Tovey, Saskia, additional, Kearsley‐Fleet, Lianne, additional, Schaefer, Martin, additional, Ribeiro, Sandra Lucia Euzebio, additional, Al‐Emadi, Samar, additional, Hasseli, Rebecca, additional, Müller‐Ladner, Ulf, additional, Specker, Christof, additional, Schulze‐Koops, Hendrik, additional, Bernardes, Miguel, additional, Machado Fraga, Vanessa, additional, Rodrigues, Ana Maria, additional, Sparks, Jeffrey A., additional, Ljung, Lotta, additional, Di Giuseppe, Daniela, additional, Tidblad, Liselotte, additional, Wise, Leanna, additional, Duarte‐García, Alí, additional, Ugarte‐Gil, Manuel F., additional, Colunga‐Pedraza, Iris Jazmín, additional, Martínez‐Martínez, Marco Ulises, additional, Alpizar‐Rodriguez, Deshire, additional, Xavier, Ricardo Machado, additional, Isnardi, Carolina A, additional, Pera, Mariana, additional, Pons‐Estel, Guillermo, additional, Izadi, Zara, additional, Gianfrancesco, Milena A, additional, Carrara, Greta, additional, Scirè, Carlo Alberto, additional, Zanetti, Anna, additional, and Machado, Pedro M, additional

Published
2023
Full Text
View/download PDF

26. Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases

Author

Hasseli, Rebecca, primary, Richter, Jutta G., additional, Hoyer, Bimba Franziska, additional, Lorenz, Hanns-Martin, additional, Pfeil, Alexander, additional, Regierer, Anne Constanze, additional, Schmeiser, Tim, additional, Strangfeld, Anja, additional, Voll, Reinhard E, additional, Krause, Andreas, additional, Reckert, Sabine, additional, Gräßler, Anett, additional, Saar, Petra, additional, Kapelle, Andreas, additional, Backhaus, Marina, additional, Blank, Norbert, additional, Henes, Joerg, additional, Osiek, Silke, additional, Knothe, Anna, additional, Hoese, Guido, additional, Brandt-Jürgens, Jan, additional, Maltzahn, Anja, additional, Specker, Christof, additional, Müller-Ladner, Ulf, additional, and Schulze-Koops, Hendrik, additional

Published
2023
Full Text
View/download PDF

27. Characteristics associated with poor COVID-19 outcomes in people with psoriasis, psoriatic arthritis and axial spondyloarthritis

Author

Machado, Pedro M, Schäfer, Martin, Mahil, Satveer K, Liew, Jean, Gossec, Laure, Dand, Nick, Pfeil, Alexander, Strangfeld, Anja, Regierer, Anne Constanze, Fautrel, Bruno, Alonso, Carla Gimena, Saad, Carla G S, Griffiths, Christopher E M, Lomater, Claudia, Miceli-Richard, Corinne, Wendling, Daniel, Alpizar Rodriguez, Deshire, Wiek, Dieter, Mateus, Elsa F, Sirotich, Emily, Soriano, Enrique R, Ribeiro, Francinne Machado, Omura, Felipe, Rajão Martins, Frederico, Santos, Helena, Dau, Jonathan, Barker, Jonathan N, Hausmann, Jonathan, Hyrich, Kimme L, Gensler, Lianne, Silva, Ligia, Jacobsohn, Lindsay, Carmona, Loreto, Pinheiro, Marcelo M, Zelaya, Marcos David, Severina, María de Los Ángeles, Yates, Mark, Dubreuil, Maureen, Gore-Massy, Monique, Romeo, Nicoletta, Haroon, Nigil, Sufka, Paul, Grainger, Rebecca, Hasseli, Rebecca, Lawson-Tovey, Saskia, Bhana, Suleman, Pham, Thao, Olofsson, Tor, Bautista-Molano, Wilson, Wallace, Zachary S, Yiu, Zenas Z N, Yazdany, Jinoos, Robinson, Philip C, Smith, Catherine H, Centro de Estudos de Doenças Crónicas (CEDOC), and NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)

Subjects
SDG 3 - Good Health and Well-being
Abstract

Funding The study received support from the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR). OBJECTIVES: To investigate factors associated with severe COVID-19 in people with psoriasis (PsO), psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA). METHODS: Demographic data, clinical characteristics and COVID-19 outcome severity of adults with PsO, PsA and axSpA were obtained from two international physician-reported registries. A three-point ordinal COVID-19 severity scale was defined: no hospitalisation, hospitalisation (and no death) and death. ORs were estimated using multivariable ordinal logistic regression. RESULTS: Of 5045 cases, 18.3% had PsO, 45.5% PsA and 36.3% axSpA. Most (83.6%) were not hospitalised, 14.6% were hospitalised and 1.8% died. Older age was non-linearly associated with COVID-19 severity. Male sex (OR 1.54, 95% CI 1.30 to 1.83), cardiovascular, respiratory, renal, metabolic and cancer comorbidities (ORs 1.25-2.89), moderate/high disease activity and/or glucocorticoid use (ORs 1.39-2.23, vs remission/low disease activity and no glucocorticoids) were associated with increased odds of severe COVID-19. Later pandemic time periods (ORs 0.42-0.52, vs until 15 June 2020), PsO (OR 0.49, 95% CI 0.37 to 0.65, vs PsA) and baseline exposure to TNFi, IL17i and IL-23i/IL-12+23i (OR 0.57, 95% CI 0.44 to 0.73; OR 0.62, 95% CI 0.45 to 0.87; OR 0.67, 95% CI 0.45 to 0.98; respectively; vs no disease-modifying antirheumatic drug) were associated with reduced odds of severe COVID-19. CONCLUSION: Older age, male sex, comorbidity burden, higher disease activity and glucocorticoid intake were associated with more severe COVID-19. Later pandemic time periods, PsO and exposure to TNFi, IL17i and IL-23i/IL-12+23i were associated with less severe COVID-19. These findings will enable risk stratification and inform management decisions for patients with PsO, PsA and axSpA during COVID-19 waves or similar future respiratory pandemics. publishersversion published

Published
2023

30. No Increased Lethality in Covid-19 in Patients with Inflammatory Rheumatic Diseases Compared to the General Population - a Comparison of Two German Registries -

Author

Hasseli, Rebecca, primary, Hanses, Frank, additional, Stecher, Melanie, additional, Specker, Christof, additional, Weise, Tobias, additional, Borgmann, Stefan, additional, Haselberger, Martina, additional, Hertenstein, Bernd, additional, Hower, Martin, additional, Hoyer, Bimba Franziska, additional, Koll, Carolin, additional, Krause, Andreas, additional, von Lilienfeld-Toal, Marie, additional, Lorenz, Hanns-Martin, additional, Merle, Uta, additional, Nunes de Miranda, Susana M., additional, Pletz, Mathias W., additional, Regierer, Anne, additional, Richter, Jutta G., additional, Rieg, Siegbert R., additional, Römmele, Christoph, additional, Rüthrich, Maria M., additional, Schulze-Koops, Hendrik, additional, Strangfeld, Anja, additional, Vehreschild, Maria, additional, Voit, Florian, additional, Voll, Reinhard, additional, Vehreschild, Jörg Janne, additional, Leipsic, Jonathon, additional, and Pfeil, Alexander, additional

Published
2023
Full Text
View/download PDF

32. Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases

Author

Izadi, Zara, Gianfrancesco, Milena A., Aguirre, Alfredo, Strangfeld, Anja, Mateus, Elsa F., Hyrich, Kimme L., Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Seet, Andrea M., Schmajuk, Gabriela, Jacobsohn, Lindsay, Katz, Patricia, Rush, Stephanie, Al-Emadi, Samar, Sparks, Jeffrey A., Hsu, Tiffany Y.T., Patel, Naomi J., Wise, Leanna, Gilbert, Emily, Duarte-García, Alí, Valenzuela-Almada, Maria O., Ugarte-Gil, Manuel F., Ribeiro, Sandra Lúcia Euzébio, de Oliveira Marinho, Adriana, de Azevedo Valadares, Lilian David, Giuseppe, Daniela Di, Hasseli, Rebecca, Richter, Jutta G., Pfeil, Alexander, Schmeiser, Tim, Isnardi, Carolina A., Reyes Torres, Alvaro A., Alle, Gelsomina, Saurit, Verónica, Zanetti, Anna, Carrara, Greta, Labreuche, Julien, Barnetche, Thomas, Herasse, Muriel, Plassart, Samira, Santos, Maria José, Rodrigues, Ana Maria, Robinson, Philip C., Machado, Pedro M., Sirotich, Emily, Liew, Jean W., Hausmann, Jonathan S., NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM), and Centro de Estudos de Doenças Crónicas (CEDOC)

Subjects
Rheumatology
Abstract

Funding Information: We acknowledge financial support from the ACR and EULAR. The ACR and EULAR were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Publisher Copyright: © 2022 The Authors. ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology. Objective: Some patients with rheumatic diseases might be at higher risk for coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). We aimed to develop a prediction model for COVID-19 ARDS in this population and to create a simple risk score calculator for use in clinical settings. Methods: Data were derived from the COVID-19 Global Rheumatology Alliance Registry from March 24, 2020, to May 12, 2021. Seven machine learning classifiers were trained on ARDS outcomes using 83 variables obtained at COVID-19 diagnosis. Predictive performance was assessed in a US test set and was validated in patients from four countries with independent registries using area under the curve (AUC), accuracy, sensitivity, and specificity. A simple risk score calculator was developed using a regression model incorporating the most influential predictors from the best performing classifier. Results: The study included 8633 patients from 74 countries, of whom 523 (6%) had ARDS. Gradient boosting had the highest mean AUC (0.78; 95% confidence interval [CI]: 0.67-0.88) and was considered the top performing classifier. Ten predictors were identified as key risk factors and were included in a regression model. The regression model that predicted ARDS with 71% (95% CI: 61%-83%) sensitivity in the test set, and with sensitivities ranging from 61% to 80% in countries with independent registries, was used to develop the risk score calculator. Conclusion: We were able to predict ARDS with good sensitivity using information readily available at COVID-19 diagnosis. The proposed risk score calculator has the potential to guide risk stratification for treatments, such as monoclonal antibodies, that have potential to reduce COVID-19 disease progression. publishersversion published

Published
2022

33. Durchbruchinfektionen bei vollständig geimpften Patienten mit entzündlich-rheumatischen Erkrankungen – Daten aus dem COVID19-Rheuma.de-Register

Author

Hasseli, Rebecca, Hoyer, Bimba F., Huppke, Liam, Lorenz, Hanns-Martin, Pfeil, Alexander, Regierer, Anne, Richter, Jutta, Schmeiser, Tim, Strangfeld, Anja, Voll, Reinhard, Krause, Andreas, Schulze-Koops, Hendrik, Specker, Christof, and Müller-Ladner, Ulf

Subjects
Medicine and health
Abstract

Einleitung: COVID-19-Impfungen reduzieren nachweislich das Risiko für schwere Verläufe einer SARS-CoV-2-Infektion. Auch bei Patienten mit entzündlich-rheumatischen Erkrankungen (ERE) und bei Patienten unter Immunmodulation konnte mehrheitlich eine ausreichende humorale Immunantwort auf [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

34. Verträglichkeit und Sicherheit von COVID-19-Impfstoffen nach Erstimpfung bei Patienten mit rheumatischen Erkrankungen

Author

Hasseli, Rebecca, Hoyer, Bimba F., Lorenz, Hanns-Martin, Pfeil, Alexander, Regierer, Anne, Richter, Jutta G., Schmeiser, Tim, Strangfeld, Anja, Voll, Reinhard, Krause, Andreas, Specker, Christof, Müller-Ladner, Ulf, and Schulze-Koops, Hendrik

Subjects
Medicine and health
Abstract

Einleitung: Zu Beginn der Impfkampagne herrschte Ungewissheit bezüglich der Verträglichkeit und Sicherheit der neuartigen Impfstoffe gegen SARS-CoV-2 bei Patienten mit rheumatischen Erkrankungen (RE) mit und ohne Immunmodulation. Es lagen insbesondere keine Daten bezüglich der Verträglichkeit [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

35. Zeitliche Trends im Verlauf von SARS-CoV-2-Infektionen seit Beginn des COVID19-Rheuma.de-Registers

Author

Hasseli, Rebecca, Hoyer, Bimba F., Lorenz, Hanns-Martin, Pfeil, Alexander, Regierer, Anne, Richter, Jutta, Schmeiser, Tim, Strangfeld, Anja, Voll, Reinhard, Krause, Andreas, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, and Specker, Christof

Subjects
Medicine and health
Abstract

Einleitung: Seit Beginn der Pandemie haben Virusmutationen, Zulassung von Impfstoffen, Medikamente zur Therapie von COVID-19 sowie der fortschreitende Informationsgewinn zum Umgang mit dem Coronavirus Einfluss auf den Verlauf der Pandemie genommen. Zur Frage, inwieweit sich die klinischen Verläufe [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022
Full Text
View/download PDF

36. Additional file 1 of Small fiber involvement is independent from clinical pain in late-onset Pompe disease

Author

Enax-Krumova, Elena K., Dahlhaus, Iris, Görlach, Jonas, Claeys, Kristl G., Montagnese, Federica, Schneider, llka, Sturm, Dietrich, Fangerau, Tanja, Schlierbach, Hannah, Roth, Angela, Wanschitz, Julia V., Löscher, Wolfgang N., Güttsches, Anne-Katrin, Vielhaber, Stefan, Hasseli, Rebecca, Zunk, Lea, Krämer, Heidrun H., Hahn, Andreas, Schoser, Benedikt, Rosenbohm, Angela, and Schänzer, Anne

Abstract

Additional file 1: Table S1: Clinical and demographic findings in 35 patients with LOPD

Published
2022
Full Text
View/download PDF

37. Additional file 4 of Small fiber involvement is independent from clinical pain in late-onset Pompe disease

Author

Enax-Krumova, Elena K., Dahlhaus, Iris, Görlach, Jonas, Claeys, Kristl G., Montagnese, Federica, Schneider, llka, Sturm, Dietrich, Fangerau, Tanja, Schlierbach, Hannah, Roth, Angela, Wanschitz, Julia V., Löscher, Wolfgang N., Güttsches, Anne-Katrin, Vielhaber, Stefan, Hasseli, Rebecca, Zunk, Lea, Krämer, Heidrun H., Hahn, Andreas, Schoser, Benedikt, Rosenbohm, Angela, and Schänzer, Anne

Subjects
integumentary system
Abstract

Additional file 4: Table S4: Morphometric analysis of skin biopsies from twenty healthy controls

Published
2022
Full Text
View/download PDF

38. Additional file 2 of Small fiber involvement is independent from clinical pain in late-onset Pompe disease

Author

Enax-Krumova, Elena K., Dahlhaus, Iris, Görlach, Jonas, Claeys, Kristl G., Montagnese, Federica, Schneider, llka, Sturm, Dietrich, Fangerau, Tanja, Schlierbach, Hannah, Roth, Angela, Wanschitz, Julia V., Löscher, Wolfgang N., Güttsches, Anne-Katrin, Vielhaber, Stefan, Hasseli, Rebecca, Zunk, Lea, Krämer, Heidrun H., Hahn, Andreas, Schoser, Benedikt, Rosenbohm, Angela, and Schänzer, Anne

Abstract

Additional file 2: Table S2: Self-reported data on pain, anxiety and depression symptoms in 35 patients with LOPD

Published
2022
Full Text
View/download PDF

39. Additional file 3 of Small fiber involvement is independent from clinical pain in late-onset Pompe disease

Author

Enax-Krumova, Elena K., Dahlhaus, Iris, Görlach, Jonas, Claeys, Kristl G., Montagnese, Federica, Schneider, llka, Sturm, Dietrich, Fangerau, Tanja, Schlierbach, Hannah, Roth, Angela, Wanschitz, Julia V., Löscher, Wolfgang N., Güttsches, Anne-Katrin, Vielhaber, Stefan, Hasseli, Rebecca, Zunk, Lea, Krämer, Heidrun H., Hahn, Andreas, Schoser, Benedikt, Rosenbohm, Angela, and Schänzer, Anne

Subjects
integumentary system
Abstract

Additional file 3: Table S3: Morphometric analysis of skin biopsies from 35 patients with LOPD

Published
2022
Full Text
View/download PDF

40. Country-Level Factors Associated With COVID-19-Related Death in People With Rheumatic Disease: Results From the COVID-19 Global Rheumatology Alliance Registry

Author

Izadi, Zara, primary, Gianfrancesco, Milena A., additional, Schmajuk, Gabriela, additional, Jacobsohn, Lindsay, additional, Katz, Patricia, additional, Rush, Stephanie, additional, Ja, Clairissa, additional, Taylor, Tiffany, additional, Shidara, Kie, additional, Danila, Maria I., additional, Wysham, Katherine D., additional, Strangfeld, Anja, additional, Frãzao Mateus, Elsa, additional, Hyrich, Kimme L., additional, Gossec, Laure, additional, Carmona, Loreto, additional, Lawson-Tovey, Saskia, additional, Kearsley-Fleet, Lianne, additional, Schaefer, Martin, additional, Al-Emadi, Samar, additional, Sparks, Jeffrey A., additional, Hsu, Tiffany Y-T, additional, Patel, Naomi J., additional, Wise, Leanna, additional, Gilbert, Emily, additional, Duarte-García, Alí, additional, Valenzuela-Almada, Maria O., additional, Ugarte-Gil, Manuel F., additional, Ljung, Lotta, additional, Scirè, Carlo A., additional, Carrara, Greta, additional, Hachulla, Eric, additional, RICHEZ, Christophe, additional, CACOUB, Patrice, additional, Thomas, Thierry, additional, Santos, Maria J., additional, Bernardes, Miguel, additional, Hasseli, Rebecca, additional, Regierer, Anne, additional, Schulze-Koops, Hendrik, additional, Müller-Ladner, Ulf, additional, Pons-Estel, Guillermo, additional, Tanten, Romina, additional, Nieto, Romina E., additional, Pisoni, Cecilia Nora, additional, Tissera, Yohana S., additional, Xavier, Ricardo, additional, Marques, Claudia D. Lopes, additional, Pileggi, Gecilmara Cristina Salviato, additional, Robinson, Philip C., additional, Machado, Pedro M., additional, Sirotich, Emily, additional, Liew, Jean W., additional, Hausmann, Jonathan S., additional, Sufka, Paul, additional, Grainger, Rebecca, additional, Bhana, Suleman, additional, Gore-Massy, Monique, additional, Wallace, Zachary S., additional, Yazdany, Jinoos, additional, and Registry, Global Rheumatology Alliance, additional

Published
2022
Full Text
View/download PDF

41. Outcome of SARS-CoV-2 infection in patients with rheumatoid arthritis under treatment with Janus kinase inhibitors compared to etanercept

Author

Hasseli, Rebecca, Hoyer, Bimba F., Krause, Andreas, Lorenz, Hanns-Martin, Pfeil, Alexander, Regierer, Anne, Richter, Jutta, Schmeiser, Tim, Strangfeld, Anja, Schulze-Koops, Hendrik, Voll, Reinhard, Specker, Christof, and Müller-Ladner, Ulf

Subjects
ddc: 610, 610 Medical sciences, Medicine
Abstract

Introduction: Various immunosuppressants have been used as anti-inflammatory drugs and cytokine inhibitors to treat the complications of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) disease 2019 (COVID-19). Of these, there has been particular interest in the Janus kinase (JAK) inhibitors[for full text, please go to the a.m. URL], Deutscher Rheumatologiekongress 2021, 49. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 35. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), Wissenschaftliche Herbsttagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

Published
2021
Full Text
View/download PDF

42. Factors associated with severe COVID-19 in people with idiopathic inflammatory myopathy: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.

Author

Su-Ann Yeoh, Gianfrancesco, Milena, Lawson-Tovey, Saskia, Hyrich, Kimme L., Strangfeld, Anja, Gossec, Laure, Carmona, Loreto, Mateus, Elsa F., Schäfer, Martin, Richez, Christophe, Hachulla, Eric, Holmqvist, Marie, Scirè, Carlo Alberto, Lorenz, Hanns-Martin, Voll, Reinhard E., Hasseli, Rebecca, Jayatilleke, Arundathi, Hsu, Tiffany Y.-T., D'Silva, Kristin M., and Pimentel-Quiroz, Victor R.

Published
2022
Full Text
View/download PDF

44. TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD

Author

Regierer, Anne Constanze, primary, Hasseli, Rebecca, additional, Schäfer, Martin, additional, Hoyer, Bimba F, additional, Krause, Andreas, additional, Lorenz, Hanns-Martin, additional, Pfeil, Alexander, additional, Richter, Jutta, additional, Schmeiser, Tim, additional, Schulze-Koops, Hendrik, additional, Strangfeld, Anja, additional, Voll, Reinhard E, additional, Specker, Christof, additional, and Mueller-Ladner, Ulf, additional

Published
2021
Full Text
View/download PDF

45. NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection

Author

Pawlitzki, Marc, primary, Nelke, Christopher, additional, Rolfes, Leoni, additional, Hasseli, Rebecca, additional, Tomaras, Stylianos, additional, Feist, Eugen, additional, Schänzer, Anne, additional, Räuber, Saskia, additional, Regner, Liesa, additional, Preuße, Corinna, additional, Allenbach, Yves, additional, Benveniste, Olivier, additional, Wiendl, Heinz, additional, Stenzel, Werner, additional, Meuth, Sven G., additional, and Ruck, Tobias, additional

Published
2021
Full Text
View/download PDF

46. Deutsches Register www.Covid19-Rheuma.de

Author

Hasseli, Rebecca, Pfeil, Alexander, Hoyer, Bimba Franziska, Lorenz, Hanns-Martin, Regierer, Anne C., Richter, Jutta G., Schmeiser, Tim, Strangfeld, Anja, Voll, Reinhard E., Krause, Andreas, Schulze-Koops, Hendrik, Müller-Ladner, Ulf, Specker, Christof, and Justus Liebig University Giessen

Subjects
ddc:610
Published
2021
Full Text
View/download PDF

48. Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry : a retrospective cohort study

Author

Sattui, Sebastian E., Conway, Richard, Putman, Michael S., Seet, Andrea M., Gianfrancesco, Milena A., Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L., Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Maldonado, Federico Nicolas, Mariz, Henrique Ataide, Studart, Samia Araujo de Sousa, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stephane, Maria, Alexandre T. J., Chazerain, Pascal, Hasseli, Rebecca, Muller-Ladner, Ulf, Hoyer, Bimba F., Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Al-Emadi, Samar, Sparks, Jeffrey A., Hsu, Tiffany Y-T, D'Silva, Kristin M., Patel, Naomi J., Wise, Leanna, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-Garcia, Ali, Ugarte-Gil, Manuel, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F., Hyrich, Kimme L., Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S., Sufka, Paul, Bhana, Suleman, Liew, Jean W., Grainger, Rebecca, Machado, Pedro M., Wallace, Zachary S., Yazdany, Jinoos, Robinson, Philip C., Sattui, Sebastian E., Conway, Richard, Putman, Michael S., Seet, Andrea M., Gianfrancesco, Milena A., Beins, Kaley, Hill, Catherine, Liew, David, Mackie, Sarah L., Mehta, Puja, Neill, Lorna, Gomez, Gimena, Salinas, Maria Isabel Haye, Maldonado, Federico Nicolas, Mariz, Henrique Ataide, Studart, Samia Araujo de Sousa, Araujo, Nafice Costa, Knight, Ann, Rozza, Davide, Quartuccio, Luca, Samson, Maxime, Bally, Stephane, Maria, Alexandre T. J., Chazerain, Pascal, Hasseli, Rebecca, Muller-Ladner, Ulf, Hoyer, Bimba F., Voll, Reinhard, Torres, Rita Pinheiro, Luis, Mariana, Ribeirio, Sandra Lucia Euzebio, Al-Emadi, Samar, Sparks, Jeffrey A., Hsu, Tiffany Y-T, D'Silva, Kristin M., Patel, Naomi J., Wise, Leanna, Gilbert, Emily, Almada, Maria Valenzuela, Duarte-Garcia, Ali, Ugarte-Gil, Manuel, Jacobsohn, Lindsay, Izadi, Zara, Strangfeld, Anja, Mateus, Elsa F., Hyrich, Kimme L., Gossec, Laure, Carmona, Loreto, Lawson-Tovey, Saskia, Kearsley-Fleet, Lianne, Schaefer, Martin, Sirotich, Emily, Hausmann, Jonathan S., Sufka, Paul, Bhana, Suleman, Liew, Jean W., Grainger, Rebecca, Machado, Pedro M., Wallace, Zachary S., Yazdany, Jinoos, and Robinson, Philip C.

Abstract

Background Patients with primary systemic vasculitis or polymyalgia rheumatica might be at a high risk for poor COVID-19 outcomes due to the treatments used, the potential organ damage cause by primary systemic vasculitis, and the demographic factors associated with these conditions. We therefore aimed to investigate factors associated with COVID-19 outcomes in patients with primary systemic vasculitis or polymyalgia rheumatica. Methods In this retrospective cohort study, adult patients (aged >= 18 years) diagnosed with COVID-19 between March 12, 2020, and April 12, 2021, who had a history of primary systemic vasculitis (antineutrophil cytoplasmic antibody [ANCA]-associated vasculitis, giant cell arteritis, Behcet's syndrome, or other vasculitis) or polymyalgia rheumatica, and were reported to the COVID-19 Global Rheumatology Alliance registry were included. To assess COVID-19 outcomes in patients, we used an ordinal COVID-19 severity scale, defined as: (1) no hospitalisation; (2) hospitalisation without supplemental oxygen; (3) hospitalisation with any supplemental oxygen or ventilation; or (4) death. Multivariable ordinal logistic regression analyses were used to estimate odds ratios (ORs), adjusting for age, sex, time period, number of comorbidities, smoking status, obesity, glucocorticoid use, disease activity, region, and medication category. Analyses were also stratified by type of rheumatic disease. Findings Of 1202 eligible patients identified in the registry, 733 (61.0%) were women arid 469 (39.0%) were men, and their mean age was 63.8 years (SD 17.1). A total of 374 (31.1%) patients had polymyalgia rheumatica, 353 (29.4%) had ANCA-associated vasculitis, 183 (15.2%) had giant cell arteritis, 112 (9.3%) had Behcet's syndrome, and 180 (15.0%) had other vasculitis. Of 1020 (84. 9%) patients with outcome data, 512 (S0.2%) were not hospitalised, 114 (11.2%) were hospitalised and did not receive supplemental oxygen, 239 (23 - 4%) were hospitalised and received

Published
2021
Full Text
View/download PDF

49. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19.

Author

UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Izadi, Zara, Brenner, Erica J, Mahil, Satveer K, Dand, Nick, Yiu, Zenas Z N, Yates, Mark, Ungaro, Ryan C, Zhang, Xian, Agrawal, Manasi, Colombel, Jean-Frederic, Gianfrancesco, Milena A, Hyrich, Kimme L, Strangfeld, Anja, Carmona, Loreto, Mateus, Elsa F, Lawson-Tovey, Saskia, Klingberg, Eva, Cuomo, Giovanna, Caprioli, Marta, Cruz-Machado, Ana Rita, Mazeda Pereira, Ana Carolina, Hasseli, Rebecca, Pfeil, Alexander, Lorenz, Hanns-Martin, Hoyer, Bimba Franziska, Trupin, Laura, Rush, Stephanie, Katz, Patricia, Schmajuk, Gabriela, Jacobsohn, Lindsay, Seet, Andrea M, Al Emadi, Samar, Wise, Leanna, Gilbert, Emily L, Duarte-García, Alí, Valenzuela-Almada, Maria O, Isnardi, Carolina A, Quintana, Rosana, Soriano, Enrique R, Hsu, Tiffany Y-T, D'Silva, Kristin M, Sparks, Jeffrey A, Patel, Naomi J, Xavier, Ricardo Machado, Marques, Claudia Diniz Lopes, Kakehasi, Adriana Maria, Flipo, René-Marc, Claudepierre, Pascal, Cantagrel, Alain, Goupille, Philippe, Wallace, Zachary S, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Hausmann, Jonathan S, Liew, Jean W, Sirotich, Emily, Sufka, Paul, Robinson, Philip C, Machado, Pedro M, Griffiths, Christopher E M, Barker, Jonathan N, Smith, Catherine H, Yazdany, Jinoos, Kappelman, Michael D, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection, Rahier, Jean-François, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - (MGD) Service de gastro-entérologie, Izadi, Zara, Brenner, Erica J, Mahil, Satveer K, Dand, Nick, Yiu, Zenas Z N, Yates, Mark, Ungaro, Ryan C, Zhang, Xian, Agrawal, Manasi, Colombel, Jean-Frederic, Gianfrancesco, Milena A, Hyrich, Kimme L, Strangfeld, Anja, Carmona, Loreto, Mateus, Elsa F, Lawson-Tovey, Saskia, Klingberg, Eva, Cuomo, Giovanna, Caprioli, Marta, Cruz-Machado, Ana Rita, Mazeda Pereira, Ana Carolina, Hasseli, Rebecca, Pfeil, Alexander, Lorenz, Hanns-Martin, Hoyer, Bimba Franziska, Trupin, Laura, Rush, Stephanie, Katz, Patricia, Schmajuk, Gabriela, Jacobsohn, Lindsay, Seet, Andrea M, Al Emadi, Samar, Wise, Leanna, Gilbert, Emily L, Duarte-García, Alí, Valenzuela-Almada, Maria O, Isnardi, Carolina A, Quintana, Rosana, Soriano, Enrique R, Hsu, Tiffany Y-T, D'Silva, Kristin M, Sparks, Jeffrey A, Patel, Naomi J, Xavier, Ricardo Machado, Marques, Claudia Diniz Lopes, Kakehasi, Adriana Maria, Flipo, René-Marc, Claudepierre, Pascal, Cantagrel, Alain, Goupille, Philippe, Wallace, Zachary S, Bhana, Suleman, Costello, Wendy, Grainger, Rebecca, Hausmann, Jonathan S, Liew, Jean W, Sirotich, Emily, Sufka, Paul, Robinson, Philip C, Machado, Pedro M, Griffiths, Christopher E M, Barker, Jonathan N, Smith, Catherine H, Yazdany, Jinoos, Kappelman, Michael D, Psoriasis Patient Registry for Outcomes, Therapy and Epidemiology of COVID-19 Infection, and Rahier, Jean-François

Abstract

Although tumor necrosis factor (TNF) inhibitors are widely prescribed globally because of their ability to ameliorate shared immune pathways across immune-mediated inflammatory diseases (IMIDs), the impact of COVID-19 among individuals with IMIDs who are receiving TNF inhibitors remains insufficiently understood. To examine the association between the receipt of TNF inhibitor monotherapy and the risk of COVID-19-associated hospitalization or death compared with other commonly prescribed immunomodulatory treatment regimens among adult patients with IMIDs. This cohort study was a pooled analysis of data from 3 international COVID-19 registries comprising individuals with rheumatic diseases, inflammatory bowel disease, and psoriasis from March 12, 2020, to February 1, 2021. Clinicians directly reported COVID-19 outcomes as well as demographic and clinical characteristics of individuals with IMIDs and confirmed or suspected COVID-19 using online data entry portals. Adults (age ≥18 years) with a diagnosis of inflammatory arthritis, inflammatory bowel disease, or psoriasis were included. Treatment exposure categories included TNF inhibitor monotherapy (reference treatment), TNF inhibitors in combination with methotrexate therapy, TNF inhibitors in combination with azathioprine/6-mercaptopurine therapy, methotrexate monotherapy, azathioprine/6-mercaptopurine monotherapy, and Janus kinase (Jak) inhibitor monotherapy. The main outcome was COVID-19-associated hospitalization or death. Registry-level analyses and a pooled analysis of data across the 3 registries were conducted using multilevel multivariable logistic regression models, adjusting for demographic and clinical characteristics and accounting for country, calendar month, and registry-level correlations. A total of 6077 patients from 74 countries were included in the analyses; of those, 3215 individuals (52.9%) were from Europe, 3563 individuals (58.6%) were female, and the mean (SD) age was 48.8 (16.5) years. The mo

Published
2021

50. Do patients with rheumatoid arthritis show a different course of COVID-19 compared to patients with spondyloarthritis?

Author

Hasseli, Rebecca, Pfeil, Alexander, Hoyer, Bimba F., Krause, Andreas, Lorenz, Hanns-Martin, Richter, Jutta G., Schmeiser, Tim, Voll, Reinhard E., Schulze-Koops, Hendrik, Specker, Christof, and Müller-Ladner, Ulf

Subjects
Arthritis, Rheumatoid, Rheumatology, SARS-CoV-2, Immunology, Arthritis, Psoriatic, Spondylarthritis, Medizin, Immunology and Allergy, COVID-19, Humans, Middle Aged
Abstract

Rheumatoid arthritis (RA) and spondyloarthritis (SpA) are the most common inflammatory rheumatic diseases (IRD). The aim of this study was to elucidate differences in the outcome of SARS-CoV-2 infection in RA- and SpA-patients.Data from the German COVID-19 registry for IRD patients from 30th March to 16th November 2020 were analysed. 208 RA and SpA patients were included in the study, matched for gender and age.104 SpA patients (40% patients with ankylosing spondylitis, 54% with psoriatic arthritis and 6% with enteropathic arthritis) were compared to 104 RA patients. For both groups, median age was 56 years. TNF-i treatment was reported in 45% of the SpA and in 19% of RA patients (p=0.001). Glucocorticoids were used in 13% of the SpA and in 40% of the RA patients (p=0.001). In both groups, the majority of the patients (97% SpA, 95% RA) recovered from COVID-19. Hospitalisation was needed in 16% of the SpA and in 30% of the RA patients (p=0.05), and oxygen treatment in 10% and 18% respectively (p=ns). Three versus six (p=ns) fatal courses were reported in the SpA versus the RA group.The study revealed that the hospitalisation rate during COVID-19 infection, but not the mortality, was significantly higher in RA as compared to SpA patients. This could be explained either by different treatment strategies or by different susceptibilities of the two diseases.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results